Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis

Eric L. Simpson(Oregon Health & Science University), Dimittri Delevry(Regeneron (United States)), Randy Prescilla(Sanofi (United States)), Zhen Chen(Taixing People's Hospital), Lauren Nelson(RTI Health Solutions), Isabelle Guillemin, Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases), Diane Whalley(RTI Health Solutions), Ashish Bansal(Regeneron (United States))
Dermatology and Therapy
May 27, 2021
10.1007/s13555-021-00543-7
Cited by 19

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
|Journal of the American Academy of Dermatology|2016|564
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516